
    
      A double-blind, placebo-controlled, multicenter study of sirukumab as adjunctive treatment to
      a monoaminergic antidepressant in adults with major depressive disorder. Participants will be
      randomly assigned to receive either placebo or sirukumab 50 milligram (mg) at a ratio of 1:1
      at Day 1, 28 and 56. Participants will primarily be assessed for change from baseline in
      Hamilton Depression Rating Scale (HDRS17) score at Week 12. Safety will be monitored
      throughout the study.
    
  